HK1201268A1 - Bicyclic piperazine compounds - Google Patents
Bicyclic piperazine compoundsInfo
- Publication number
- HK1201268A1 HK1201268A1 HK15101808.3A HK15101808A HK1201268A1 HK 1201268 A1 HK1201268 A1 HK 1201268A1 HK 15101808 A HK15101808 A HK 15101808A HK 1201268 A1 HK1201268 A1 HK 1201268A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- piperazine compounds
- bicyclic piperazine
- bicyclic
- compounds
- piperazine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161555396P | 2011-11-03 | 2011-11-03 | |
| PCT/US2012/063171 WO2013067260A1 (en) | 2011-11-03 | 2012-11-02 | Bicyclic piperazine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1201268A1 true HK1201268A1 (en) | 2015-08-28 |
Family
ID=47279001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15101808.3A HK1201268A1 (en) | 2011-11-03 | 2015-02-18 | Bicyclic piperazine compounds |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8722676B2 (ru) |
| EP (1) | EP2773640B1 (ru) |
| JP (1) | JP5808869B2 (ru) |
| KR (1) | KR20140096100A (ru) |
| CN (1) | CN104105697B (ru) |
| BR (1) | BR112014010391A2 (ru) |
| CA (1) | CA2852964A1 (ru) |
| ES (1) | ES2552514T3 (ru) |
| HK (1) | HK1201268A1 (ru) |
| MX (1) | MX2014005285A (ru) |
| RU (1) | RU2628616C2 (ru) |
| WO (1) | WO2013067260A1 (ru) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101673728B1 (ko) * | 2011-12-09 | 2016-11-07 | 에프. 호프만-라 로슈 아게 | 브루톤 티로신 키나아제의 억제제 |
| EP2813504A1 (en) * | 2013-06-14 | 2014-12-17 | Institut Quimic De Sarriá Cets, Fundació Privada | 4-Amino-6-(2,6-dichlorophenyl)-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8H)-one derivatives, synthesis and uses thereof |
| CA2912359A1 (en) | 2013-07-03 | 2015-01-08 | F. Hoffmann-La Roche Ag | Heteroaryl pyridone and aza-pyridone amide compounds |
| CN103360399B (zh) * | 2013-08-02 | 2016-03-02 | 北京大学 | 6-芳基取代-咪唑-[1,2-b]哒嗪类衍生物，其制备方法及用途 |
| KR101813830B1 (ko) * | 2013-12-05 | 2017-12-29 | 에프. 호프만-라 로슈 아게 | 친전자성 작용기를 갖는 헤테로아릴 피리돈 및 아자-피리돈 화합물 |
| US9802920B2 (en) | 2013-12-13 | 2017-10-31 | Hoffman-La Roche Inc. | Inhibitors of bruton's tyrosine kinase |
| CA2942204A1 (en) | 2014-03-12 | 2015-09-17 | Novartis Ag | Combination comprising a btk inhibitor and an akt inhibitor |
| WO2015157955A1 (en) | 2014-04-17 | 2015-10-22 | Abbvie Inc. | Heterocyclic btk inhibit ors |
| CA2948436A1 (en) | 2014-05-23 | 2015-11-26 | Active Biotech Ab | Novel compounds useful as s100-inhibitors |
| CN111303159A (zh) | 2014-10-02 | 2020-06-19 | 豪夫迈·罗氏有限公司 | 用于治疗由布鲁顿酪氨酸激酶(btk)介导的疾病的吡唑甲酰胺化合物 |
| EP3212645B1 (en) | 2014-10-27 | 2018-11-28 | F.Hoffmann-La Roche Ag | Process for making tricyclic lactam compounds |
| MY196130A (en) * | 2015-03-10 | 2023-03-16 | Aurigene Discovery Tech Ltd | 1,2,4-Oxadiazole and Thiadiazole Compounds as Immunomodulators |
| CN104744463A (zh) * | 2015-03-31 | 2015-07-01 | 山东友帮生化科技有限公司 | 6-氯-8-溴咪唑并[1,2-a]吡啶的合成方法 |
| FR3037959B1 (fr) * | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CN109890809A (zh) | 2016-11-08 | 2019-06-14 | 默克专利股份公司 | 作为pfkfb的抑制剂的取代的喹喔啉衍生物 |
| TW201831478A (zh) | 2016-12-02 | 2018-09-01 | 瑞士商赫孚孟拉羅股份公司 | 雙環醯胺化合物及其使用方法 |
| HRP20211553T1 (hr) * | 2016-12-15 | 2021-12-24 | F. Hoffmann - La Roche Ag | Postupak za pripravu inhibitora btk |
| JP7076741B2 (ja) | 2016-12-27 | 2022-05-30 | 国立研究開発法人理化学研究所 | Ｂｍｐシグナル阻害化合物 |
| CN109206435B (zh) * | 2017-06-29 | 2020-09-08 | 中国医药研究开发中心有限公司 | 噻吩并[3,2-d]嘧啶类化合物及其制备方法和医药用途 |
| AR112274A1 (es) | 2017-07-14 | 2019-10-09 | Hoffmann La Roche | Compuestos bicíclicos de cetona y sus métodos de uso |
| MX2020003451A (es) | 2017-10-31 | 2020-08-03 | Hoffmann La Roche | Sulfonas y sulfoxidos biciclicos y metodos de uso de los mismos. |
| CN110256446B (zh) * | 2018-08-01 | 2021-12-14 | 上海海雁医药科技有限公司 | 苯并杂环取代的环戊二烯并[4,5]吡咯并吡嗪-1-酮衍生物及其应用 |
| WO2020176403A1 (en) | 2019-02-25 | 2020-09-03 | Newave Pharmaceutical Inc. | Inhibitor of btk and mutants thereof |
| US20220363689A1 (en) | 2019-10-05 | 2022-11-17 | Newave Pharmaceutical Inc. | Inhibitor of btk and mutants thereof |
| KR20220158712A (ko) * | 2020-02-20 | 2022-12-01 | 허치슨 메디파르마 리미티드 | 헤테로아릴 헤테로사이클릭 화합물 및 그의 용도 |
| WO2021219071A1 (en) * | 2020-04-30 | 2021-11-04 | Beigene (Beijing) Co., Ltd. | Process for preparing protac btk degraders |
| CN115715291A (zh) * | 2020-06-18 | 2023-02-24 | 上海华汇拓医药科技有限公司 | 布鲁顿酪氨酸激酶抑制剂及其制备方法 |
| KR20230104125A (ko) * | 2020-09-21 | 2023-07-07 | 허치슨 메디파르마 리미티드 | 헤테로아릴 헤테로사이클릭 화합물 및 이의 용도 |
| US20230382900A1 (en) | 2020-10-30 | 2023-11-30 | Newave Pharmaceutical Inc. | Inhibitors of btk |
| WO2022133184A1 (en) | 2020-12-20 | 2022-06-23 | Newave Pharmaceutical Inc. | Btk degrader |
| WO2023143491A1 (zh) * | 2022-01-28 | 2023-08-03 | 和记黄埔医药（上海）有限公司 | 7,8-二氢-2h-环戊二烯并吡咯并吡嗪酮化合物的合成方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5583024A (en) | 1985-12-02 | 1996-12-10 | The Regents Of The University Of California | Recombinant expression of Coleoptera luciferase |
| DE4224133A1 (de) * | 1992-07-22 | 1994-01-27 | Thomae Gmbh Dr K | Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| JPH08336393A (ja) | 1995-04-13 | 1996-12-24 | Mitsubishi Chem Corp | 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法 |
| US6602677B1 (en) | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
| WO2003006151A1 (en) | 2001-07-12 | 2003-01-23 | Avecia Limited | Microencapsulated catalyst, methods of preparation and methods of use thereof |
| US6514989B1 (en) * | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
| WO2005014599A1 (en) * | 2003-06-04 | 2005-02-17 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds |
| WO2005005429A1 (en) | 2003-06-30 | 2005-01-20 | Cellular Genomics, Inc. | Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds |
| MX2007005643A (es) | 2004-11-10 | 2008-03-13 | Cgi Pharmaceuticals Inc | Ciertas imidazo [1,2-a] pirazin-8-ilaminas, metodo para su elaboracion y metodo de uso de las mismas. |
| TW200716551A (en) | 2005-03-10 | 2007-05-01 | Cgi Pharmaceuticals Inc | Certain substituted amides, method of making, and method of use thereof |
| EA019983B1 (ru) | 2005-10-07 | 2014-07-30 | Экселиксис, Инк. | Ингибиторы mek и способы их применения |
| PE20080839A1 (es) | 2006-09-11 | 2008-08-23 | Cgi Pharmaceuticals Inc | Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas |
| AR063946A1 (es) | 2006-09-11 | 2009-03-04 | Cgi Pharmaceuticals Inc | Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
| US7838523B2 (en) | 2006-09-11 | 2010-11-23 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
| BRPI0622054B8 (pt) * | 2006-09-22 | 2021-05-25 | Oxford Amherst Llc | composto e composição farmacêutica |
| CL2008002793A1 (es) | 2007-09-20 | 2009-09-04 | Cgi Pharmaceuticals Inc | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras |
| US8426441B2 (en) | 2007-12-14 | 2013-04-23 | Roche Palo Alto Llc | Inhibitors of bruton's tyrosine kinase |
| WO2009077334A1 (en) * | 2007-12-14 | 2009-06-25 | F. Hoffmann-La Roche Ag | Novel imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives |
| US7683064B2 (en) | 2008-02-05 | 2010-03-23 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| WO2009137596A1 (en) * | 2008-05-06 | 2009-11-12 | Cgi Pharmaceuticals, Inc. | Substituted amides, method of making, and use as btk inhibitors |
| EP2297142B1 (en) | 2008-06-24 | 2015-10-14 | F. Hoffmann-La Roche AG | Novel substituted pyridin-2-ones and pyridazin-3-ones |
| ES2420854T3 (es) | 2008-07-02 | 2013-08-27 | F. Hoffmann-La Roche Ag | Nuevas fenilpirazinonas como inhibidores de quinasas |
| ES2552681T3 (es) | 2008-07-15 | 2015-12-01 | F. Hoffmann-La Roche Ag | Nuevas fenil-imidazopiridinas y piridazinas |
| KR101358532B1 (ko) * | 2008-07-18 | 2014-02-05 | 에프. 호프만-라 로슈 아게 | 신규한 페닐이미다조피라진 |
| WO2010011837A1 (en) * | 2008-07-24 | 2010-01-28 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| WO2010056875A1 (en) | 2008-11-12 | 2010-05-20 | Cgi Pharmaceuticals, Inc. | Pyridazinones and their use as btk inhibitors |
| WO2010068810A2 (en) * | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
| JP5656976B2 (ja) * | 2009-04-29 | 2015-01-21 | ローカス ファーマシューティカルズ インコーポレイテッド | ピロロトリアジン化合物 |
| EP2473049B1 (en) * | 2009-09-04 | 2018-11-28 | Biogen MA Inc. | Bruton's tyrosine kinase inhibitors |
| US9562056B2 (en) * | 2010-03-11 | 2017-02-07 | Gilead Connecticut, Inc. | Imidazopyridines Syk inhibitors |
| CA3034600C (en) | 2010-05-07 | 2020-11-10 | Genentech, Inc. | Pyridone and aza-pyridone compounds and methods of use |
| AR082590A1 (es) | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
| CA2809662C (en) | 2010-09-01 | 2019-04-16 | Gilead Connecticut, Inc. | Pyridazinones, method of making, and method of use thereof |
| CA2809836C (en) | 2010-09-01 | 2019-01-15 | Gilead Connecticut, Inc. | Pyridinones/pyrazinones, method of making, and method of use thereof for the treatment of disorders mediated by bruton's tyrosine kinase |
| CN103582637B (zh) | 2011-05-17 | 2015-08-12 | 弗·哈夫曼-拉罗切有限公司 | 酪氨酸激酶抑制剂 |
| WO2013024078A1 (en) | 2011-08-17 | 2013-02-21 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
-
2012
- 2012-11-02 ES ES12795138.2T patent/ES2552514T3/es active Active
- 2012-11-02 RU RU2014121073A patent/RU2628616C2/ru not_active IP Right Cessation
- 2012-11-02 EP EP12795138.2A patent/EP2773640B1/en not_active Not-in-force
- 2012-11-02 JP JP2014540110A patent/JP5808869B2/ja not_active Expired - Fee Related
- 2012-11-02 CN CN201280065858.5A patent/CN104105697B/zh not_active Expired - Fee Related
- 2012-11-02 KR KR1020147014768A patent/KR20140096100A/ko not_active Application Discontinuation
- 2012-11-02 WO PCT/US2012/063171 patent/WO2013067260A1/en active Application Filing
- 2012-11-02 US US13/667,121 patent/US8722676B2/en active Active
- 2012-11-02 CA CA2852964A patent/CA2852964A1/en not_active Abandoned
- 2012-11-02 MX MX2014005285A patent/MX2014005285A/es active IP Right Grant
- 2012-11-02 BR BR112014010391A patent/BR112014010391A2/pt not_active IP Right Cessation
-
2015
- 2015-02-18 HK HK15101808.3A patent/HK1201268A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US8722676B2 (en) | 2014-05-13 |
| MX2014005285A (es) | 2014-05-30 |
| ES2552514T3 (es) | 2015-11-30 |
| CN104105697B (zh) | 2016-11-09 |
| KR20140096100A (ko) | 2014-08-04 |
| WO2013067260A1 (en) | 2013-05-10 |
| CN104105697A (zh) | 2014-10-15 |
| EP2773640B1 (en) | 2015-08-19 |
| BR112014010391A2 (pt) | 2017-04-18 |
| JP5808869B2 (ja) | 2015-11-10 |
| EP2773640A1 (en) | 2014-09-10 |
| JP2014532715A (ja) | 2014-12-08 |
| CA2852964A1 (en) | 2013-05-10 |
| RU2014121073A (ru) | 2015-12-10 |
| RU2628616C2 (ru) | 2017-08-21 |
| US20130116262A1 (en) | 2013-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1201268A1 (en) | Bicyclic piperazine compounds | |
| IL232570A0 (en) | Bicyclic derivatives of dihydroisoquinoline-1-one | |
| GB201109763D0 (en) | Compounds | |
| GB201106395D0 (en) | Compounds | |
| ZA201401577B (en) | New bicyclic dihydroquinoline-2-one derivatives | |
| GB201107197D0 (en) | Compounds | |
| EP2772485A4 (en) | BICYCLIC CONNECTION | |
| HK1206340A1 (en) | New bicyclic thiophenylamide compounds | |
| ZA201403513B (en) | Bicyclic heterocyclic compound | |
| HK1189880A1 (en) | Benzodioxole piperazine compounds | |
| GB201110938D0 (en) | Compounds | |
| GB201105659D0 (en) | Compounds | |
| GB201118613D0 (en) | Compounds | |
| GB201119703D0 (en) | Compounds | |
| GB201115828D0 (en) | Compounds | |
| GB201115827D0 (en) | Compounds | |
| GB201115829D0 (en) | Compounds | |
| GB201114195D0 (en) | Compounds | |
| GB201111440D0 (en) | Compounds | |
| GB201109915D0 (en) | Compounds | |
| GB201109597D0 (en) | Compounds | |
| GB201107204D0 (en) | Compounds | |
| GB201106262D0 (en) | Compounds | |
| GB201106178D0 (en) | Compounds | |
| GB201105531D0 (en) | Compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20211105 |